Epizyme Inc (NASDAQ:EPZM) has revealed its corporate plans and vision that it will build upon over the next few years until the year 2020.

The company’s revealed strategy will mainly focus on four developmental activities that include the expansion of its clinical initiative for tazemetostat. The expansion will aid utilization in earlier therapy models in conjunction with a cocktail of regimens as well as five new types of tumors.

The next transformative activity will be the transition into a commercial-stage business, and this will be possible thanks to the global launch of tazemetostat for patients that have specific genetically defined solid tumors as well as patients suffering from non-Hodgkin lymphoma (NHL). The company will also focus on expanding its pipeline with a minimum of three new potential oncology products used that are in clinical development. It will also be supported by a strong set of preclinical drugs.

The final transformative activity will be the establishment of Epizyme’s leadership in epigenetics as well as the remodeling of chromatin in oncology. The company’s president and CEO, Robert Bazemore stated that the whole company is focused on its vision of revolutionizing cancer treatments especially for diseases without solutions. He further added that the firm is committed towards innovation in its pipeline and scientific excellence. These factors have been vital towards the company’s journey to becoming an industry leader in epigenetic therapies.

Epizyme is a pharmaceutical company that is focused on creating epigenetic therapies for cancer treatment. The firm is focused on a few vital activities that are designed to speed up the development of tazemetostat so that it may offer its benefits to patients as soon as possible. The drug has already demonstrated some positive impacts on both solid tumors and hematologic malignancies.

The company is currently supporting clinical trials for the treatment. Peter Ho, the Chief Medical Officer at Epizyme, stated that the company has a few but important achievements to anticipate for the better part of 2016 including the research findings from the five-arm phase 2 trials of tazemetostat for patients with NHL.